Pancreatic Cancer
📧 Sign up to get email alerts when something new happens for Pancreatic Cancer.
Sign up freeTop drugs studied for this disease
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Pancreatic Cancer Screening Study in Individuals With New-Onset or Deteriorating Diabetes Mellitus
This clinical trial update describes a pancreatic cancer screening study for individuals with new-onset or deteriorating diabetes mellitus, …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Safety, PK and Efficacy of QXL138AM in Patients With Solid Tumors and Multiple Myeloma [Phase 1]
Phase 1 clinical trial update on QXL138AM assessing safety, pharmacokinetics, and preliminary efficacy in patients with solid tumors and mul…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: The Vanguard Study: Testing a New Way to Screen for Cancer [NA]
The Vanguard Study is a National Cancer Institute–sponsored cancer screening trial that is currently recruiting to evaluate a new screening …
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Study to Assess Adverse Events and Pharmacokinetics in Adult Participants With Non-Small Cell Lung Cancer, Head and Neck Squamous Cell Carcinoma and Other Solid Tumors, Receiving Intravenous Infusion of Azirkitug Alone or in Combination(s) With Budigalimab, Bevacizumab, or Telisotuzumab Adizutecan [Phase 1]
Phase 1 trial evaluating the safety, adverse events, and pharmacokinetics of Azirkitug alone or in combination with Budigalimab, Bevacizumab…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Targeted Therapy Directed by Genetic Testing in Treating Patients With Advanced Refractory Solid Tumors, Lymphomas, or Multiple Myeloma (The MATCH Screening Trial) [Phase 2]
This Phase 2 MATCH Screening Trial update describes ongoing evaluation of targeted therapies matched to genetic alterations in patients with…
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Measuring the Effects of Talazoparib in Patients With Advanced Cancer and DNA Repair Variations [Phase 2]
This clinical trial update describes a Phase 2 study evaluating talazoparib in patients with advanced cancers and DNA repair variations, and…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: A Study to Evaluate Chemotherapy With or Without INCB161734 in Previously Untreated, KRAS G12D-Mutated Metastatic Pancreatic Ductal Adenocarcinoma [Phase 3]
A Phase 3 clinical trial evaluating chemotherapy with or without INCB161734 in untreated metastatic pancreatic ductal adenocarcinoma with KR…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: SURGIMEDIA: Utilization of Multimedia for Enhanced Surgical Consent [NA]
The update describes a trial evaluating multimedia-based consent for pancreatic cancer surgery, sponsored by UNC Lineberger Comprehensive Ca…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Gemcitabine Hydrochloride, Dasatinib, and Erlotinib Hydrochloride in Treating Patients With Pancreatic Cancer That Is Metastatic or Cannot Be Removed by Surgery [Phase 1]
Phase 1 study evaluating the combination of gemcitabine hydrochloride, dasatinib, and erlotinib hydrochloride in patients with metastatic or…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: Ropidoxuridine in Treating Patients With Advanced Gastrointestinal Cancer Undergoing Radiation Therapy [Phase 1]
This Phase 1 trial update describes evaluating ropidoxuridine as a radiosensitizer in patients with advanced gastrointestinal cancers underg…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: GDC-0449 and Erlotinib Hydrochloride With or Without Gemcitabine Hydrochloride in Treating Patients With Metastatic Pancreatic Cancer or Solid Tumors That Cannot Be Removed by Surgery [Phase 1]
Phase 1 trial evaluating GDC-0449 (vismodegib) and erlotinib hydrochloride, with or without gemcitabine hydrochloride, in metastatic pancrea…
-
CLINICAL_TRIALS research · 2026-04-13Clinical Trial Update: M6620 and Irinotecan Hydrochloride in Treating Patients With Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery [Phase 1]
This is a Phase 1 trial updating the safety and dosing of M6620 in combination with irinotecan in patients with metastatic or unresectable s…
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: A Phase 2 Study of T-DXd in Patients With Selected HER2 Expressing Tumors [Phase 2]
A Phase 2 clinical trial update for trastuzumab deruxtecan (Enhertu) in HER2-expressing tumors, including bladder, biliary tract, cervical, …
-
CLINICAL_TRIALS research · 2026-04-09Clinical Trial Update: Phase 2 Futibatinib in Combination With PD-1 Antibody Based Standard of Care in Solid Tumors [Phase 2]
Phase 2 study evaluating futibatinib in combination with a PD-1 antibody-based standard of care for locally advanced unresectable or metasta…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: Testing Higher Dose Radiation Therapy for Locally Advanced Pancreatic Cancer [Phase 3]
A Phase 3 trial is evaluating higher-dose radiation therapy for locally advanced unresectable pancreatic ductal adenocarcinoma, and recruitm…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: ctDNA-based Minimal Residual Disease Detection for Resected Pancreatic Adenocarcinoma
Ongoing clinical trial evaluating ctDNA-based minimal residual disease detection in patients with resected pancreatic cancer; the study is c…
-
CLINICAL_TRIALS research · 2026-04-08Clinical Trial Update: A Study of NovoTTF-200T(P) in Combination With Gemcitabine and Nab-Paclitaxel for Resectable Pancreatic Adenocarcinoma [Phase 2]
A Phase 2 clinical trial evaluating NovoTTF-200T(P) in combination with gemcitabine and nab-paclitaxel for resectable pancreatic cancer is c…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Collection of Circulating Biomarkers in Pancreatic Cancer
This clinical trial update notes recruitment for a study that collects circulating biomarkers in pancreatic cancer. The aim is to study dise…
-
CLINICAL_TRIALS research · 2026-04-07Clinical Trial Update: Collecting Blood Samples From Patients With and Without Cancer to Evaluate Tests for Early Cancer Detection
A clinical trial is enrolling people with and without cancer to collect blood samples and evaluate tests for early cancer detection across m…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Alpha Radiation Emitters Device (DaRT) With Chemotherapy for the Treatment of Locally Advanced and Metastatic Pancreatic Cancer [NA]
A clinical trial exploring the DaRT alpha radiation emitter device in combination with chemotherapy for locally advanced and metastatic panc…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Daraxonrasib and Daraxonrasib + GnP as First-line Treatment in Patients With Metastatic Pancreatic Adenocarcinoma [Phase 3]
A Phase 3 clinical trial evaluating Daraxonrasib alone and in combination with gemcitabine and nab-paclitaxel as first-line therapy for meta…
-
CLINICAL_TRIALS research · 2026-04-06Clinical Trial Update: Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 3]
A Phase 3 clinical trial evaluating Daraxonrasib (RMC-6236) in patients with resected pancreatic ductal adenocarcinoma is currently recruiti…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: Prehab for Pancreatic Cancer Surgery [NA]
This clinical trial update notes a study on prehabilitation for pancreatic cancer surgery that is currently recruiting, sponsored by the Uni…
-
CLINICAL_TRIALS research · 2026-04-03Clinical Trial Update: PTM-101 in Pancreatic Ductal Adenocarcinoma (PDAC) [Phase 1]
A Phase 1 clinical trial of PTM-101 for pancreatic ductal adenocarcinoma and related locally advanced or borderline resectable disease is cu…
-
CLINICAL_TRIALS research · 2026-04-02Clinical Trial Update: Atezolizumab + Cabozantinib in Patients w/ Metastatic, Refractory Pancreatic Cancer [Phase 2]
This entry reports a Phase 2 clinical trial evaluating the combination of atezolizumab and cabozantinib in patients with metastatic, refract…